Clinical Results of Targeting Prostate Cancer with ADCs
Important targets for targeting prostate cancer (PCa) include: prostate-specific membrane antigen (PSMA), six-transmembrane epithelial antigen 1 (STEAP-1), solute carrier family 44 member 4 (SLC44A4), trophoblast cell surface antigen (Trop-2) and B7-H3. Introduction Antibody-drug conjugates (ADCs) consist of a linker, payload, and monoclonal antibody (mAb). They combine the advantages of high specificity targeting and potent killing … Read more